1 Cash-Heavy Stock to Target This Week and 2 We IgnoreA surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face c...
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology StocksQuarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
Spotting Winners: AbbVie (NYSE:ABBV) And Therapeutics Stocks In Q4The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stoc...
Therapeutics Q4 Earnings: Novavax (NASDAQ:NVAX) Simply the BestAs the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Novav...
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
Q4 Earnings Highs And Lows: Gilead Sciences (NASDAQ:GILD) Vs The Rest Of The Therapeutics StocksLooking back on therapeutics stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Gilead Sciences (
NASDAQ:GILD) and its peers....
Novavax (NVAX): Buy, Sell, or Hold Post Q4 Earnings?Novavax has been treading water for the past six months, recording a small loss of 2.9% while holding steady at $8.34. Is there a buying opportunity in Novav...
3 Reasons NVAX is Risky and 1 Stock to Buy InsteadOver the last six months, Novavax shares have sunk to $8.21, producing a disappointing 7.7% loss - worse than the S&P 500’s 2.1% drop. This might have invest...
1 Russell 2000 Stock with Exciting Potential and 2 We AvoidThe Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size ...
AMN Healthcare Services, DaVita, Bristol-Myers Squibb, Novavax, and AbbVie Shares Plummet, What You Need To KnowWhat Happened? A number of stocks fell in the afternoon session after reports revealed that the US may impose up to 100% tariffs on imports of branded and pa...
2 Growth Stocks Set to Flourishand 1 We QuestionGrowth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 wil...
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The PackLooking back on biotechnology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Incyte (
NASDAQ:INCY) and its peers. The bio...
Novavax (NVAX) Stock Trades Down, Here Is WhyWhat Happened? Shares of vaccine biotechnology company Novavax (
NASDAQ:NVAX) fell 4.1% in the afternoon session after major indices including the S&P 500 and...
3 Stocks Under $50 That Concern UsStocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline...
Unpacking Q4 Earnings: Halozyme Therapeutics (NASDAQ:HALO) In The Context Of Other Therapeutics StocksAs the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Haloz...
Therapeutics Stocks Q4 In Review: United Therapeutics (NASDAQ:UTHR) Vs PeersQuarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
2 Healthcare Stocks to Target This Week and 1 That UnderwhelmFrom novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advanceme...
Q4 Earnings Highlights: BioMarin Pharmaceutical (NASDAQ:BMRN) Vs The Rest Of The Therapeutics StocksEarnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at BioMarin Pharmaceutical (NASD...
Therapeutics Stocks Q4 Teardown: Moderna (NASDAQ:MRNA) Vs The RestQuarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
3 Profitable Stocks That Concern UsNot all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...
Q4 Earnings Outperformers: Vertex Pharmaceuticals (NASDAQ:VRTX) And The Rest Of The Therapeutics StocksAs the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Vertex Pharmaceuticals (NASD...
Winners And Losers Of Q4: Biogen (NASDAQ:BIIB) Vs The Rest Of The Therapeutics StocksLet’s dig into the relative performance of Biogen (
NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics earnings season. Over the next ...
Q4 Earnings Highs And Lows: Amgen (NASDAQ:AMGN) Vs The Rest Of The Therapeutics StocksEarnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Amgen (
NASDAQ:AMGN) and its p...
Why Novavax (NVAX) Shares Are Falling TodayShares of vaccine biotechnology company Novavax (
NASDAQ:NVAX) fell 8.7% in the afternoon session after the release of a key inflation report revealed prices paid to U.S. producers rose more than anticipated in January.
